ELUTE

What ELUTE does

Elute, Inc. is a clinical-stage medical device company headquartered in Salt Lake City, Utah, that develops polymer-controlled drug delivery devices to prevent and treat orthopedic surgical bone infections. Founded in 2011, the company operates a technology platform that enables controlled local delivery of antibiotics and other therapeutic agents from resorbable synthetic bone void fillers over extended periods (days to weeks). Elute's product portfolio consists of two distinct bone graft substitute products: BonVie+, an FDA-cleared resorbable synthetic bone graft substitute composed of calcium carbonate, hydroxyapatite, and biocompatible polymers engineered for programmed resorption over 3-12 months; and EP Granules with Tobramycin, an investigational antibiotic-eluting bone void filler providing 8 weeks of targeted local tobramycin delivery for surgical treatment of periprosthetic joint infections (PJI).

The company's underlying technology combines a carbonate-apatite composition mimicking human bone mineral with polymer-controlled antibiotic release kinetics, validated through multiple peer-reviewed publications in journals including European Cells and Materials (2019), Journal of Biomedical Materials Research (2013, 2015), and PLoS ONE (2015). The platform is protected by a USPTO notice of allowance (October 2017) for "Implantable Devices for Bone or Joint Defects," providing broad patent protection for combination drug/device products capable of delivering antibiotics for up to eight weeks while supporting bone regeneration. EP Granules is currently in a pivotal multicenter clinical trial (MAGIC) at prestigious sites including Hospital for Special Surgery and Rothman Orthopaedic Institute, which collectively perform over 17,000 hip and knee procedures annually.

Elute generates revenue through one-time direct sales of its FDA-cleared BonVie+ product to hospitals and orthopedic surgeons, supported by a strategic distribution partnership with Spartan Medical for US market access announced in 2024-2025. The go-to-market approach is enterprise field sales targeting orthopedic surgeons, joint reconstruction specialists, and hospitals performing joint arthroplasty and trauma surgery. Pricing is negotiated through hospital contracts and group purchasing organizations rather than publicly disclosed. The company is in very early commercial stage: BonVie+ launched in September 2025 while EP Granules remains investigational pending MAGIC trial completion, with reported headcount of 1-10 employees consistent with a lean clinical-stage medtech startup.

Name

ELUTE

Legal name

Elute, Inc.

Website

https://elutinc.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Elute, Inc. is a clinical-stage medical device company developing polymer-controlled drug delivery bone void fillers to treat orthopedic surgical infections, with BonVie+ (FDA-cleared) and EP Granules with Tobramycin (investigational) targeting orthopedic surgeons and hospitals.

Ownership category

akta.pro rank

Product category

Orthopedic Bone Graft Substitutes

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Orthopedic medical devices
• Drug-eluting implants
• Bone graft substitutes
• Antibiotic delivery systems
• Resorbable bone void fillers

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Elute generates revenue through the sale of its FDA-cleared medical device products, including BonVie+ (resorbable bone graft substitute) and the investigational EP Granules with Tobramycin. Revenue is generated through direct commercial sales to hospitals and orthopedic surgeons, supported by distribution partnerships such as Spartan Medical.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Elute is a clinical-stage medical device company that designs and develops resorbable synthetic bone void fillers with polymer-controlled drug delivery capabilities. Its commercial offering is BonVie+, an FDA-cleared resorbable synthetic bone graft substitute made of calcium carbonate, hydroxyapatite, and biocompatible polymers that resorbs over 3–12 months. Its lead investigational product, EP Granules with Tobramycin, delivers up to 8 weeks of targeted local antibiotic therapy for the treatment of periprosthetic joint infections while simultaneously serving as a bone void filler.

Product overview

Elute is a clinical-stage medical device company developing patented drug-eluting devices with controlled and sustained therapeutic release. The company's product portfolio consists of two distinct bone graft substitute products: EP Granules with Tobramycin (investigational antibiotic-eluting device for treating periprosthetic joint infections) and BonVie+ (FDA-cleared resorbable synthetic bone graft substitute for bone void filling). Both products leverage the company's polymer-controlled drug delivery technology platform but serve different clinical needs—one focused on infection treatment with local antibiotic delivery, the other on bone restoration without therapeutic agents.

Differentiator

Problem solved

Functional benefit

Brands

• BonVie+: Resorbable synthetic bone graft substitute intended to fill bony voids or gaps in the skeletal system, including extremities and pelvis. Made from calcium carbonate, hydroxyapatite, and biocompatible polymers, engineered for programmed resorption over 3-12 months.
• EP Granules with Tobramycin

Products and services

• BonVie+ BonVie+ is a resorbable synthetic bone graft substitute made from calcium carbonate, hydroxyapatite, and biocompatible polymers that fills bony voids or gaps in the skeletal system (extremities and pelvis). It is engineered for programmed resorption over 3–12 months, allowing new bone to grow into the space during healing without seromas or wound drainage, for orthopedic surgeons and hospitals performing bone void filling in extremities and pelvis.
• EP Granules with Tobramycin EP Granules with Tobramycin is an investigational antibiotic-eluting synthetic bone void filler that provides 8 weeks of targeted local delivery of tobramycin for the surgical treatment of periprosthetic joint infections (PJI), with undetectable systemic exposure minimizing organ toxicity and resorption that replaces bone lost due to infection. Limited to investigational use in the United States, for orthopedic surgeons and hospitals participating in the MAGIC clinical trial.

Quantifiable outcome

• 8 weeks of targeted local antibiotic delivery
• +3 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Spartan MedicalcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Elute announced a strategic partnership with Spartan Medical for distribution and market access of its bone void filler products in the US market. Spartan Medical serves as a channel partner helping make Elute's products available to hospitals and orthopedic surgeons.
• Hospital for Special Surgery (HSS)coreStrategic or Co-development Partner · 30 November 2021Following FDA IDE authorization, HSS agreed to become a clinical site to evaluate EP Granules with Tobramycin. HSS is the world's leading academic medical center for musculoskeletal health, ranked No. 1 in orthopedics by U.S. News & World Report for 12 consecutive years. Dr. Amar Ranawat, Professor of Clinical Orthopaedic Surgery at Weill Cornell Medical College and attending at HSS, serves as the principal investigator.
• Rothman Orthopaedic Institute / Thomas Jefferson University HospitalcoreStrategic or Co-development Partner · 30 November 2021Rothman Orthopaedic Institute and Jefferson University Hospital joined as clinical trial sites following FDA IDE authorization. Dr. Javad Parvizi, a world-renowned expert in periprosthetic joint infection and Director of Clinical Research at Rothman, serves as investigator. Rothman collectively performs over 17,000 hip and knee procedures annually.
• AO Foundation (Switzerland)minorStrategic or Co-development PartnerDr. David W. Grainger serves as a scientific advisor to the AO Foundation in Switzerland and its affiliated Synthes Orthopaedics (now part of Johnson & Johnson's DePuy division), the leader in orthopedic trauma devices.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BoneSupport AB: BoneSupport markets CERAMENT, an injectable antibiotic-eluting bone void filler used in orthopedic infection management. It is the closest direct competitor to Elute's EP Granules with Tobramycin in the drug-eluting BVF category for PJI and bone infection.
• Biocomposites: Biocomposites manufactures Stimulan, a calcium sulfate-based bone void filler that can be loaded with antibiotics for orthopedic infection treatment. It competes directly with Elute's antibiotic-eluting BVF platform for PJI and bone defect applications.
• Heraeus Medical: Heraeus Medical produces PALACOS bone cements pre-loaded with antibiotics (gentamicin) for joint arthroplasty infection prophylaxis. It competes with Elute in local antibiotic delivery for orthopedic surgical infections.

Broad incumbents

• Anika Therapeutics: Anika Therapeutics develops joint preservation and bone repair products including hyaluronic acid-based therapies and surgical orthobiologics. It overlaps with Elute's orthopedic regenerative and joint health focus, and Elute board member Cheryl Blanchard serves as Anika's CEO.
• Stryker: Stryker is a global orthopedic medical device leader offering bone graft substitutes, joint replacement implants, and infection management products. Its broad orthopedics portfolio and large sales force compete with Elute across the bone void filler and PJI treatment space.
• Zimmer Biomet: Zimmer Biomet is one of the largest orthopedic device companies globally, offering bone grafts, joint reconstruction implants, and biologics for infection management. It competes with Elute across bone void filling and joint arthroplasty applications.
• DePuy Synthes (Johnson & Johnson): DePuy Synthes, Johnson & Johnson's orthopedic arm, offers bone graft substitutes and trauma implants. Co-founder David Grainger previously advised Synthes Orthopaedics, and DePuy is a major competitor in the bone graft and orthopedic trauma market.
• Smith+Nephew: Smith+Nephew provides orthopedic reconstruction, sports medicine, and advanced wound management including infection-related products. Its orthobiologics and bone graft portfolio overlaps with Elute's bone void filler market.
• Orthofix Medical: Orthofix offers orthopedic implants, biologics, and bone growth stimulation products used in spine and orthopedic trauma. Elute board member Jon Serbousek was previously CEO of Orthofix, and the companies address overlapping bone healing and orthopedic markets.

Emerging players

• LifeNet Health: LifeNet Health is a nonprofit organization specializing in allograft bone grafts and orthobiologics for orthopedic and spine procedures. It overlaps with Elute's BonVie+ bone void filler space in providing regenerative options for bone defects.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/elute-inc.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ELUTE